Importantly, circLRBA could competitively combine with E3 ubiquitin ligase SPOP to suppress the Twist1 ubiquitination degradation and enhances PD‐L1 transcriptional activity, thus promoting EMT, immune evasion, chemoresistance and BC progression. Here, CD274 is linked to breast cancer.